Why the study?
Vascular endothelial growth factor inhibition is a cornerstone of cancer therapy but is associated with significant adverse effects, with hypertension among the most prevalent.
Provides a review of mechanisms, predictors, and management strategies for hypertension induced by vascular endothelial growth factor inhibition in cancer patients.
Synthesizes VEGF inhibitor hypertension evidence; leaves open optimal cardio-oncology protocols pending prospective trials.
Vascular endothelial growth factor inhibition has become a cornerstone of cancer therapy. Significant adverse effect is associated with these therapies, with hypertension among the most prevalent. We aim to provide a current review of the mechanisms by which these therapies induce hypertension, the risk factors and predictors of the development of hypertension, and management strategies to minimize the risk of cardiovascular complications in patients receiving vascular endothelial growth factor inhibition as part of cancer treatment.
No takes yet. Share an insight, caveat, or question.
Javier Gómez (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: